Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes
The myelodysplastic syndromes (MDS) are a heterogeneous collection of clonal hematopoietic malignancies characterized by poor overall survival owing to ineffective hematopoiesis, progressive cytopenias, and transformation to acute myelogenous leukemia [1]. Current therapeutics for MDS are based primarily on stratification into lower-risk and higher-risk disease using clinical prognostic scoring systems [2,3]. Allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy for MDS.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tania Jain, Amy E. DeZern Tags: Commentary Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biology | Cancer & Oncology | Hematology | Leukemia | Myelodysplastic Syndrome | Transplants